Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.49 |
| ▸ | CTSG | P08311 | 3/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.49 |
| ▸ | CMA1 | P23946 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7897280 | 1.00 | CA2 (0.65) | CA2SLC1A2CCR1PRSS1CTSG | |
| SCHEMBL31540126 | 0.89 | SLC1A2 (0.53) | CA2SLC1A2CTRB1LMNAALDH1A1 | |
| SCHEMBL15260867 | 0.86 | CA2 (0.66) | CA2LMNAALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL11812665 | 0.86 | CTRB1 (0.50) | CA2SLC1A2PRSS1CTSGCTRB1 | |
| SCHEMBL4681864 | 0.86 | CA2 (0.54) | CA2SLC1A2CCR1PRSS1CTSG | |
| SCHEMBL4680332 | 0.84 | CA2 (0.64) | CA2CCR1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL10118947 | 0.84 | CA2 (0.52) | CA2CCR1ALDH1A1SMN1; SMN2ADAM17 | |
| SCHEMBL8638326 | 0.82 | CA2 (0.55) | CA2RAB9AADAM17HDAC3HDAC1 | |
| SCHEMBL21310010 | 0.82 | CA2 (0.61) | CA2CCR1ALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL10893431 | 0.81 | SLC1A2 (0.50) | CA2SLC1A2CTRB1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| CN-112261939-A | Granzyme B directed imaging and therapy | 塞托赛特生物制药股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-3752145-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | Cytosite Biopharma Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2019160916-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| EP-1392655-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1198456-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1392655-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6645968-B2 | E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; | ABBOTT LABORATORIES | 2003-11-11 | — | — | US | disclosed |
| WO-2002062762-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1198456-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
| US-6180374-B1 | ENANTIOMORPHS; BIOTRANSFORMATION USING ENZYME IN PRESENCE OF AN ALCOHOL OF AN AZLACTONE | CHIROTECH TECHNOLOGY, INC. (GB) | 2001-01-30 | — | — | US | disclosed |
| EP-0726891-B1 | A METHOD FOR PREPARING TERT-LEUCINE AND ANALOGUES THEREOF IN ENANTIOMERIC FORM, AND INTERMEDIATES THEREIN | CHIROTECH TECHNOLOGY LTD (GB) | 1999-02-03 | — | — | EP | disclosed |
| EP-0726891-A1 | A METHOD FOR PREPARING $i(TERT)-LEUCINE AND ANALOGUES THEREOF IN ENANTIOMERIC FORM, AND INTERMEDIATES THEREIN | Chiroscience Limited (GB) | 1996-08-21 | — | — | EP | disclosed |
| WO-1995012573-A1 | A METHOD FOR PREPARING TERT-LEUCINE AND ANALOGUES THEREOF IN ENANTIOMERIC FORM, AND INTERMEDIATES THEREIN | CHIROSCIENCE LIMITED (GB) | 1995-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | CA2 369/4885SLC1A2 243/4885CCR1 4547/4885 |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | CA2 1885/4885SLC1A2 4468/4885CCR1 545/4885 |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | CA2 1885/4885SLC1A2 4468/4885CCR1 545/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | CA2 1885/4885SLC1A2 4468/4885CCR1 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.